Bright Minds Biosciences (NASDAQ: DRUG) — Perfil da empresa, notícias e dados financeiros
Bright Minds Biosciences develops therapies for neuropsychiatric disorders, leveraging innovative science to improve patient care.

Bright Minds Biosciences
Bright Minds Biosciences (NASDAQ:DRUG) is a company focused on developing innovative therapies for patients suffering from neuropsychiatric disorders, epilepsy, and pain. With a commitment to improving the lives of those impacted by these challenging conditions, Bright Minds Biosciences leverages cutting-edge science to create more effective and safer treatment options. Through its research and development activities, the company aims to unlock new possibilities in medical treatment and contribute significantly to the field of mental health and neurological diseases. With its dedication to advancing healthcare, Bright Minds Biosciences is driven by the objective to usher in a new era of therapeutic solutions that can transform patient care and outcomes.
Resumo
Operações
Produtos e/ou serviços de Bright Minds Biosciences
- Development of next-generation serotonergic compounds to treat neuropsychiatric and neurological disorders.
- Research on psychedelics for creating non-hallucinogenic mental health treatments.
- Innovations in the field of epilepsy, focusing on novel treatment options.
- Pioneering the use of 5-HT receptor modulators for brain health.
- Advancement in therapies for pain management without the use of opioids.
- Exploration of treatments for cognitive impairments and neurodegenerative diseases.
equipe executiva do Bright Minds Biosciences
- Ian McDonaldCo-Founder, CEO, President & Director
- Ryan E. S. K. CheungCFO & Corporate Secretary
- Jan Torleif PedersenChief Science Officer & Director
- Alex VasilkevichCOO & Senior Scientific Officer
- Emer LeahyConsultant
- Stephen D. CollinsChief Medical Officer
Últimas notícias sobre a Bright Minds Biosciences
Principais indicadores financeiros
Resultados divulgados pela Bright Minds Biosciences, em CAD.
- Cap. de mercado
- 545,7 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -13,9 mi | -12,2 mi | |
| 0 | -2,8 mi | -2,8 mi | |
| 0 | -7,4 mi | -7,4 mi | |
| 0 | -15 mi | -15 mi |